PAAT Act

The PAAT Act would amend Medicare law (Title XVIII) to require that Medicare Part D prescription drug plans (PDPs) cover certain drugs used to treat autoimmune diseases and specific blood disorders, starting in 2027 and every year thereafter. Specifically, PDP sponsors would have to include every covered Part D drug that is indicated for autoimmune diseases, hemophilia, or Von Willebrand disease. In addition, the bill would bar the use of prior authorization for these drugs more than once in a 12-month period for plan years beginning in 2027, with limited exceptions (short-term use, certain controlled substances, or drugs that require a REMS safety program). The measure also applies to Medicare Advantage plans that include prescription drug coverage (MA-PD plans).